Analysts Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) PT at $16.20

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been assigned a consensus recommendation of “Reduce” from the seven research firms that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $17.1667.

IART has been the subject of a number of recent research reports. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Citigroup reaffirmed a “neutral” rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday. BMO Capital Markets began coverage on Integra LifeSciences in a research report on Wednesday. They issued a “market perform” rating and a $19.00 price objective for the company. Truist Financial dropped their price objective on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Finally, Wall Street Zen upgraded shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors have recently added to or reduced their stakes in the company. Glenmede Trust Co. NA increased its position in shares of Integra LifeSciences by 27.4% in the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock valued at $9,276,000 after acquiring an additional 211,774 shares during the period. Access Investment Management LLC grew its stake in shares of Integra LifeSciences by 72.0% in the first quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company’s stock worth $6,034,000 after purchasing an additional 268,085 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after purchasing an additional 589,408 shares during the last quarter. Amundi increased its holdings in Integra LifeSciences by 80.8% during the 1st quarter. Amundi now owns 19,430 shares of the life sciences company’s stock valued at $183,000 after purchasing an additional 8,681 shares during the period. Finally, Maverick Capital Ltd. purchased a new position in Integra LifeSciences during the 1st quarter valued at about $679,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock opened at $18.39 on Friday. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38. Integra LifeSciences has a 52-week low of $8.70 and a 52-week high of $18.92. The company has a fifty day moving average of $16.15 and a 200-day moving average of $12.81. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -2.85, a price-to-earnings-growth ratio of 1.20 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The company had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. During the same quarter last year, the company earned $0.41 EPS. The firm’s revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities research analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.